Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axsome’s pill has a safety advantage.
Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis.
The World Health Organization has prequalified Coartem Baby, the first and only antimalarial for babies. Novartis developed this combination drug in partnership with Medicines for Malaria Venture.
Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.
As radiopharmaceuticals continue to evolve, the convergence of scientific innovation, operational practicality, and clinical expertise is opening new possibilities in oncology.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Merck’s HIV drug Idvynso could become a drug choice for patients who need to switch from Gilead Sciences’ Biktarvy for safety or tolerability reasons. The Merck combination drug pairs two molecules that bring different mechanisms of action to suppressing HIV.
Tortugas Neurosciences’ two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led by veterans of Sage Therapeutics, a neuroscience biotech that was acquired last year.
Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid?
Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera Therapeutics will give it a public listing and a private placement to support clinical development of the combined company’s cancer drug pipeline.
How to turn analytics into actual policy outcomes.
Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance.
To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis.
Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer. Both startups are on track to enter the clinic next year.
Gilead Sciences exercised its option to license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership with C4 Therapeutics is focused on developing degrader antibody drug conjugates for undisclosed cancer targets.
Insmed drug Brinsupri failed to beat a placebo in a mid-stage clinical trial testing the daily pill as a treatment for hidradenitis suppurativa, a chronic inflammatory skin disorder. Brinsupri is still projected to become a blockbuster seller in non-cystic fibrosis bronchiectasis, where it is the first approved therapy for this chronic lung condition.